Figure 7
Natalizumab decreases overall CD4 T-cell accumulation in the intestinal mucosa without differentially affecting T helper type 1 (Th1) cells or regulatory T cells (Tregs). (a) Intestinal biopsy specimens were processed for immunohistochemistry (IHC) and quantified as described in the Methods section. Comparison of CD4+ and CD8+ T cells between cohorts sampled before (pre), during (on), or after (post) natalizumab therapy were made by analysis of variance (ANOVA), using Tukey’s post-test. *P<0.05. (b) To quantify the CD4+ T-cell subsets per tissue section area, the number of individual Foxp3+ Tregs (left panel) and T-bet+ Th1 cells (right panel) were divided by the number of thousands of pixels staining positive for hematoxylin in their respective section, and comparisons between cohorts were made as in (a). (c) The ratio of Foxp3+ Tregs or Tbet+ Th1 cells to CD4+ or CD8+ pixels (each normalized to its section’s hematoxylin+ surface area) was calculated for each biopsy. Comparisons made as in (a) revealed no significant differences.
